Drug main Glenmark Pharma on Wednesday stated it has obtained ultimate approval from the US well being regulator for Tacrolimus capsules, used as immuno-suppressant. The accredited product is a generic model of Prograf Capsules of Astellas Pharm US, Inc. Tacrolimus capsule is an immunosuppressant and is used for stopping organ rejection in sure sufferers following liver, kidney, or coronary heart transplant.
Glenmark Prescription drugs Inc, USA, has been granted ultimate approval by the US Meals and Drug Administration (USFDA) for Tacrolimus Capsules USP within the strengths of zero.5 mg, 1 mg and 5 mg, Glenmark stated in a regulatory submitting.
Quoting IQVIA gross sales information for the 12 months ending September 2020, Glenmark stated the Prograf Capsules, zero.5 mg, 1 mg and 5 mg market achieved annual gross sales of roughly USD 286.eight million.
Glenmark stated present portfolio consists of 166 merchandise authorised for distribution within the US market and 45 abbreviated new drug functions are pending approval with the USFDA.
Shares of Glenmark Pharma have been buying and selling at Rs 479 per scrip on the BSE, up zero.94 per cent over the earlier shut.
(With PTI inputs)